Various non-invasive markers of early arterial wall alteration are currently available such as arterial wall thickening and stiffening, endothelial dysfunction and coronary artery calcification [1] . Of them, intima media thickness (IMT) of large artery walls, especially carotid, can be assessed by B-Mode ultrasound in a relatively simple way and represents a safe, inexpensive, precise and reproducible measure [2] . This explains why IMT is more and more widely used in clinical research: (i) for testing the value of new or emerging risk factors by means of observational or epidemiological studies in groups of patients or in general populations [3] and (ii) for evaluating effects of risk factor modifications by various drugs on the progression of early arterial wall alteration in therapeutic trials [4] . In clinical practice the measurement of IMT is not yet done as a routine investigation but the predictive value of IMT with regards to cardiovascular complications has been established in several prospective studies and suggests that IMT measurement might participate in the future in the stratification of cardiovascular risk of asymptomatic patients in primary prevention [5] . The present review describes the methods of measurement and "normal" values of IMT, the relations of IMT with atherosclerotic risk factors, cardiovascular damages and clinical events, and the effects of treatments, -namely antihypertensive and lipid lowering drugs -on IMT progression over time.
as shown by the positive relationship found between the multifactorial risk score of Framingham and carotid IMT [34] . New or emerging risk factors have been also tested with regards to their relation with carotid IMT (Table 2 ) [36 -71] . Some of them have shown consistent association with increased IMT such as various lipoproteins [35, 36, 37, 38] , psychosocial status [39, 40] , plasma viscosity [41 -42] and hyperhomocysteinemia [59, 60, 62, 63] (Table 2) . Carotid IMT has also been found to be associated with some cardiovascular alterations or organ damages [72 -93] : (i) in the brain with white matter lesions assessed by magnetic resonance imaging [87] (ii) in the heart with angiographically-assessed coronary artery disease [93] , electron beam computed tomographically-assessed coronary artery calcification [92] , and echocardiographic left ventricular hypertrophy [80, 82] (iii) in the kidneys with microalbuminuria in diabetic patients [91] (iiii) in the lower limb arteries with decreased ankle to arm systolic pressure index [76] and (iiiii) in the brachial artery with endothelial dysfunction attested by decreased vasodilatory response after reactive hyperemia post arterial occlusion [75] . All the relations of IMT with cardiovascular risk factors and organ damages indicate that increased IMT may be considered as a comprehensive picture of the alterations caused by multiple risk factors over time on the arterial walls.
Relation With Clinical Events
Several prospective studies in asymptomatic subjects in primary prevention have tested the predictive value of IMT with regards to clinical cardiovascular complications [94 -99] such as myocardial infarction or stroke ( Table 3) . The KIHD Study, in middle-aged healthy Finish men, has shown that the increase of carotid IMT (at 1mm or above) was associated with twice greater risk for acute myocardial infarction over 3 years [94] . The ARIC study in several US communities, has shown that the increase of carotid IMT (at 1 mm or above) was associated with an increased risk ratio of coronary event over a period of 4 to 7 years (risk ratio of about 2 and 5 in 45-64 years men and women, respectively) [95 -96] . The CHS Study in US elderly subjects has shown that the increase of carotid IMT (at 1.18 mm or above) was associated with a four times greater risk for combined acute myocardial infarction and stroke over 6 years [97] . The Rotterdam Study in elderly Dutch subjects has shown that each increase of 0.16 mm in IMT was accompanied with a risk ratio of 1.4 for acute myocardial or stroke over 3 years [98] . Also studies in secondary prevention, in particular the CLAS study [99] in patients with established coronary artery disease, has shown that for each 0.03 mm increase per year in common carotid IMT, the relative risk for any coronary event was 3.1. All these studies are concordant for demonstrating that increased IMT is a powerful predictor of coronary and cerebrovascular complications whatever the method and the site of measurement, including the distal common carotid far wall IMT. However the predictive power seems less strong for IMT measured only in the distal common carotid than for IMT measured at multiple extracranial carotid sites.
Therapeutic Trials On Imt
Because of its quantitative value and high precision and reproducibility rate, carotid IMT measurement is more and more frequently used in therapeutic trials to test the effects of drugs [4] , especially lipid lowering and antihypertensive drugs. A number of trials have compared effects of lipid lowering drugs (resins or statins) and placebo on the progression of carotid IMT over several years. Most of them (CLAS with Colestipol/Niacin [100] ; REGRESS [101] KAPS, [102] , LIPID and CAIUS [104] with Pravastatin; ACAPS [105] and MARS [106] with Lovastatin) have shown that active drug decreased significantly the progression of IMT as compared with placebo in high-risk asymptomatic patients and in those with established coronary artery disease. Some of these trials have also shown that the reduction in IMT progression was associated with a lower incidence of cardiovascular complications so leading to consider IMT as a surrogate marker for cardiovascular complications [99] .
Other trials have compared effects of calcium antagonists with another drug (diuretic or betabloquant) or with placebo on the progression of carotid IMT in hypertensive or coronary patients [107] [108] [109] [110] [111] . Two trials, MIDAS [107] and VHAS [108] , have not demonstrated a clear beneficial effect of calcium antagonist as compared with diuretics. The MIDAS Study concluded for no difference in IMT effects of Isradipine and hydrochlorothiazide because there was no divergence in the slope of IMT progression between both treatments but when the data were analyzed as IMT change from baseline after 3 years on treatment difference existed favoring Isradipine [107] . The VHAS study also concluded for a significant greater effect of verapamil than chlorthalidone on IMT progression but only when the slope of IMT was corrected by the initial value of IMT [108] . A substudy of the INSIGHT Trial [109] , has found a clear cut difference in the progression of carotid IMT over 4 years between Nifedipine GITS and a diuretic combination of hydrochlorothiazide and amiloride in hypertensive patients at high risk for cardiovascular disease. Lastly the PREVENT Study in coronary patients has shown that Amlodipine retarded significantly the progression of carotid IMT over 3 years as compared to placebo [111] .
Clinical Perspective Of Imt Measurement
Since Carotid IMT is a marker of early arterial wall change including atherosclerosis and/or vascular hypertrophy, its detection by B-Mode ultrasonography might participate in the diagnosis of high cardiovascular risk in primary prevention and to the decision to treat aggressively patients at risk with drug treatments of modifiable risk factors [5] . Before proposing the routine measurement of IMT in clinical practice several limitations have to be overcome, such as the standardization of methods of measurements (including the site and the analysis of the measure) and a precise definition of the threshold of IMT above which the risk of cardiovascular event can be considered to substantially increase in one individual [112] .
Conclusion
IMT assessed by B-Mode ultrasound in superficial large arteries, especially the carotid, is of major relevance with regards to the following points: (i) reflection of multiple risk factors; (ii) mirror of atherosclerotic burden and/or index of cardiovascular growth in particular in hypertension; (iii) predictor of subsequent events, (iiii) end-point for therapeutic trials. However the role of IMT measurement as a screening tool in asymptomatic patients with conventional cardiovascular risk factors is not yet clearly defined, mainly because of methodological obstacles. It can be anticipated however that identifying the presence of increased IMT in the carotid arteries of one individual with intermediate cardiovascular risk would lead to classify him into the high risk category and therefore would influence the aggressiveness with which risk factor modification is done [5] .
